The Clinical Utility of Measuring Total PSA, PSA Density, γ-seminoprotein and γ-seminoprotein/total PSA in Prostate Cancer Prediction
|
|
- Morris Ramsey
- 6 years ago
- Views:
Transcription
1 Jpn J Clin Oncol 2000;30(8) Original Articles The Clinical Utility of Measuring Total PSA, PSA Density, γ-seminoprotein and γ-seminoprotein/total PSA in Prostate Cancer Prediction Ryusei Sasaki 1, Tomonori Habuchi 1, Kazunari Sato 1, Toshiya Akao 1, Hideaki Kakinuma 1, Zhang Li-Qing 1, Wang Lizhong 1, Shigeki Matsuo 2, Shuuhei Sasaki 2,OsamuOgawa 3 and Tetsuro Kato 1 1 Department of Urology, Akita University School of Medicine, Akita, 2 Akita Municipal Hospital, Akita and 3 Kyoto University Graduate School of Medicine, Kyoto, Japan Received February 16, 2000; accepted May 17, 2000 Background: To evaluate whether serum total prostate-specific antigen (PSA), PSA density (serum total PSA level divided by prostate volume), γ-seminoprotein and γ-seminoprotein/total PSA ratio could predict prostate cancer (PCa) prior to biopsy. Methods: A total of 316 consecutive patients who had undergone transrectal prostate biopsy and/or transurethral resection were examined. The prostate volume was determined by transrectal ultrasonography (TRUS) and the ability of the above-mentioned four variables to distinguish PCa from benign prostatic hyperplasia (BPH) was evaluated. Results: PCa was detected in 61 cases. Receiver-operating characteristic (ROC) analysis revealed that both the PSA density and serum total PSA were the most useful predictors of PCa among the four variables. For the patients with a serum total PSA level of ng/ml, PSA density was significantly more accurate than total PSA (p < 0.005). An optimum PSA density value of 0.18 was chosen as a cutoff because it showed the highest sum of sensitivity and specificity, 92 and 54%, respectively. Using this PSA density cutoff, the number of biopsies could have been reduced to 57 from63% when compared with a PSA density of Conclusions: PSA density was significantly more accurate than other variables in predicting PCa. To avoid unnecessary biopsies, the PSA density cutoff value of 0.18 would be recommendable for determining a prostate biopsy for Japanese males with a serum total PSA level of ng/ml. Key words: prostate cancer prostate-specific antigen PSA density free/total PSA INTRODUCTION Prostate cancer (PCa) now constitutes a major and escalating international health problem, although the worldwide prevalence of clinical PCa varies considerably from one country to another. The lowest incidence has been reported in the Far East, especially in mainland China and Japan (1). In Japan, however, the number of new cases of PCa soared from 6482 in 1988 to 9000 in 1994, causing a 1.5-fold increase in the number of deaths due to PCa in the last 10 years (2). These figures have led epidemiologists to predict a dramatic increase in both the incidence and death rates from PCa by the year For reprints and all correspondence: Tetsuro Kato, Department of Urology, Akita University School of Medicine, Hondo, Akita, , Japan 2015 if effective improvements in prevention, early diagnosis and treatment are not made. Prostate-specific antigen (PSA) is a useful tool in the diagnosis and monitoring of men being evaluated for or who have PCa (3). The yield of PCa by prostate biopsy is >50% in patients with a serum PSA level of >10.0 ng/ml (4), while the likelihood of PCa in patients with a serum PSA level of ng/ml (intermediate serum total PSA level) is 22 27% (4). Management of subjects with a serum PSA level within this range seems to be controversial since a substantial number of patients with benign prostatic hyperplasia (BPH) are within the same range of serum PSA (5). In an effort to identify PCa and, at the same time, to reduce unnecessary biopsies, various indices, such as PSA density (6,7), free/total PSA (8 10), PSA velocity (PSAV) (11), PSA transition zone volume (PSATZ) (12,13) and age-specific PSA reference range (14), have been 2000 Foundation for Promotion of Cancer Research
2 338 The clinical utility of measuring total PSA Table 1. Age, prostate volume, serum PSA, γ-sp, γ-sp/psaandpsadensityinpatientswithpcaandbph PCa (n = 61) BPH (n =255) p Age (years) 71.8 ± 1.1 ( ) 69.4 ± 0.4 ( ) Prostate volume (ml) 33.1 ± 2.5 ( ) 38.4 ± 1.4 ( ) N.S. Total PSA (ng/ml) 29.2 ± 4.5 ( ) 7.1 ± 0.4 ( ) <0.001 γ-sp (ng/ml) 8.6 ± 1.3 ( ) 3.7 ± 0.2 ( ) <0.001 γ-sp/total PSA 0.37 ± 0.04 ( ) 0.71 ± 0.04 ( ) <0.001 PSA density (ng/ml/ml) 0.34 ± 0.04 ( ) 0.23 ± 0.01 ( ) <0.001 Data are reported as mean ± S.E. (range). N.S., not significantly different. proposed. However, these studies have mainly come from Western countries where the prevalence of PCa is much higher than that in Japan (15). In the present study, we assessed the accuracy of total PSA, γ-seminoprotein (γ-sp), PSA density and γ-sp/total PSA in predicting PCa in Japanese males. We also assessed the optimum cutoff value of PSA density for the subgroup of patients with a serum total PSA level of ng/ml in order to avoid unnecessary prostate biopsies. MATERIALS AND METHODS Between April 1995 and April 1997, pretreatment serum samples from 316 Japanese patients with clinically localized PCa or BPH were subjected to the present analysis. All patients had lower urinary tract symptoms and were referred to our institutions for urological evaluation. All the patients underwent systematic (sextant) transrectal ultrasound (TRUS)- guided needle biopsy using 18-gauge biopsy needles (Biopty, C. R. Bard, GA, USA) before initiation of treatments; a biopsy was performed even if there were no suspicious sites on digital rectal examination (DRE) and TRUS. Patients were assigned to either a PCa or a BPH group according to the pathological findings of specimens obtained by biopsy and/or transurethral resection. Thus the present subjects were selected from a community-based urological practice and do not represent a screened population. All patients with PCa were thoroughly examined for staging by DRE, serum total PSA, serum γ-sp, TRUS, intravenous urography, retrograde urethrovesicography, pelvic computed tomography (CT) and bone scanning. According to the TNM classification (16), all PCa patients were defined as having T1-3N0M0 tumors. Serum samples were obtained before performing DRE and TRUS and no patients received any hormonal therapy before blood sampling. Serum total PSA levels were measured with a Tandem-R PSA kit (Hybritech, San Diego, CA, USA). Serum γ-sp levels were measured with an enzyme immunoassay using a Chugai γ-sp kit (Chugai Pharmaceutical, Tokyo, Japan). The serum γ-sp measured with this kit has been shown to represent the serum free PSA (17). TRUS examination was performed using a TOSHIBA (Tokyo, Japan) SSA-260A CE with a 6.0 MHz multiplanar probe. With a patient in the lateral knee-tochest position, multiple transverse and longitudinal views were recorded. Prostate volume was calculated with an equation for the prostate ellipsoid (maximum length width height 0.52) (18). The PSA density was calculated by dividing the serum total PSA by the prostate volume measured by TRUS. For statistical analyses, a subgroup of patients with a serum total PSA level of between 4.1 and 10.0 ng/ml was defined as an intermediate total PSA group. The values obtained were compared using the Mann Whitney U-test for non-parametric analyses. The positive predictive value (PPV), sensitivity and specificity for the tests were calculated for total PSA, PSA density, γ-sp and γ-sp/total PSA. All statistical analyses were performed using SPSS software (SPSS, Chicago, IL, USA). The significance of total PSA, PSA density, γ-sp and γ-sp/total PSA for predicting PCa was assessed based on the receiveroperating characteristic (ROC) curve using the statistic analysis programs LABROC and CLABROC developed by Metz (19). The generalized Wilcoxon test was also used as described by Hanley and McNeil (20). Statistical differences were considered significant when p values were below RESULTS OVERALL GROUP Of 316 patients, PCa was found in 61 (19%) and BPH in 235 (81%). The mean age of patients with PCa was significantly higher than that of patients with BPH (p = 0.02). There was a significant difference in total PSA, PSA density, γ-sp and γ-sp/ PSA between patients with PCa and BPH (p < 0.001) (Table 1). The diagnostic utility of these four parameters for identifying patients with PCa was evaluated using ROC curve analysis. Figure 1 provides areas under the ROC curve (AUC) for a specified cutoff value of each parameter. An AUC assessed how well a parameter could correctly identify patients with PCa and its value indicates the likelihood of correct classification. The AUC was for PSA density, for total PSA, for γ-sp and for γ-sp/psa (Fig. 1). Significant differences in the AUCs were found between total PSA and γ-sp (p = 0.001) and between total PSA and γ-sp/psa (p = 0.001), but not between total PSA and PSA density (p =0.41) or between γ-sp and γ-sp/psa (p = 0.25). Therefore, PSA density and total PSA were considered the most powerful predictors of PCa among the four variables.
3 Jpn J Clin Oncol 2000;30(8) 339 Figure 1. Receiver-operating characteristic curves for total PSA (A), PSA density (B), γ-sp (C) and γ-sp/total PSA (D) for the 316 overall subjects. The AUC value indicates the likelihood of correct identification of prostate cancer. INTERMEDIATE PSA GROUP In total, 235 patients had a serum total PSA level between 4.1 and 10.0 ng/ml and 24 (10%) of them were histologically confirmed to have PCa. The mean age of patients with PCa was significantly higher than that of the patients with BPH (p = 0.002). There was no significant difference in total PSA, γ-sp and γ-sp/total PSA between patients with PCa and BPH (Table 2). The AUC was for PSA density, for γ-sp/total PSA,0.5910fortotalPSAand0.4724forγ-sp (Fig. 2). Significant differences were found in the AUC between PSA density and total PSA (p = 0.001), between PSA density and γ-sp (p = 0.001) and between PSA density and γ-sp/total PSA (p = 0.001). Consequently, for the intermediate total PSA group, PSA density was considered the most powerful predictor of PCa among the four variables. DIAGNOSTIC PERFORMANCE OF PSA DENSITY AT VARIOUS CUTOFF VALUES Since the ROC analysis indicated that the PSA density was the most useful variable in predicting PCa in the patients with the intermediate total PSA level, we next tried to define the optimum cutoff value for PSA density. The diagnostic performance of different thresholds for PSA density is shown in Table 3. Lowering the cutoff value to 0.11 (ng/ml/ml) resulted in a sensitivity of 100% and a specificity of 38%. Utilizing this, the number of biopsies could have been reduced to 156 (34%) from 235 and none of the PCa patients would have been missed. If the PSA density cutoff value was set at 0.15, which has been widely used for PCa detection (6,7), the sensitivity and specificity would be 92 and 47%, respectively; the number of patients requiring biopsies could have been reduced to 134 (43%) from 235 with a PCa detection rate of 92% (22/24). When the PSA density cutoff value was placed at 0.18, the sensitivity and specificity would be 92 and 54%, respectively; the number of biopsies could have been reduced to 120 (51%) with a PCa detection rate of 92% (22/24). According to this analysis, a PSA density of 0.18 (ng/ml/ml) was considered optimum because it gave the highest sum of sensitivity and specificity and could have excluded a considerable number of patients from unnecessary prostate biopsies.
4 340 The clinical utility of measuring total PSA Figure 2. Receiver-operating characteristic curves of total PSA (A), γ-sp(b),psa density(c)andγ-sp/totalpsa (D)between 4.1 and 10.0 ng/ml.the AUCvalue indicates the likelihood of correct identification of prostate cancer. Table 2. Age, prostate volume, serum PSA, γ-sp, γ-sp/psaandpsadensityinpatientswithpcaandbphwithpsa level of ng/ml PCa (n = 24) BPH (n =211) p Age (years) 74.8 ± 1.1 ( ) 70.6 ± 0.6 ( ) Prostate volume (ml) 25.8 ± 2.7 ( ) 35.0 ± 1.9 ( ) N.S. Total PSA (ng/ml) 6.9 ± 0.3 ( ) 6.9 ± 0.1 ( ) N.S. γ-sp (ng/ml) 2.8 ± 0.6 ( ) 3.1 ± 0.2 ( ) N.S. γ-sp/total PSA 0.41 ± 0.08 ( ) 0.47 ± 0.04 ( ) N.S. PSA density (ng/ml/ml) 0.34 ± 0.04 ( ) 0.26 ± 0.01 ( ) 0.02 Data are reported as mean ± S.E. (range). N.S., not significantly different. DISCUSSION Serum PSA is the most widely used tumor marker for PCa, but it is insufficient for differentiating PCa and BPH. Since the likelihood of patients with benign prostatic diseases having a serum total PSA level of ng/ml is 83 88% (4), histological confirmation is an essential prerequisite for diagnosis of PCa. Consequently, TRUS-guided systematic prostate biopsy has been the current practice for urologists who encounter such patients. For early detection of PCa, Catalona et al. (21) recommended that all patients with a serum total PSA level of >4.0 ng/ml should undergo biopsies. However, its cost and overall inadequate performance hamper TRUSguided prostate biopsy (22). Rietbergen et al. (23) reported that hematuria and hematospermia were encountered in 23.6 and 45.3% of the patients after biopsy. Fever, though it was low grade, was seen in 4.2% of the patients and 0.4% of the patients required hospitalization. Thus, although prostate biopsy is generally recognized as an essential test for PCa (22), screening methods with low morbidity have become an important issue in recent years.
5 Jpn J Clin Oncol 2000;30(8) 341 Table 3. Diagnostic performance of PSA density at a PSA level of ng/ml PSAD TP FN FP TN Sensitivity Specificity PPV Biopsy Cancer cutoff value (%) (%) spared (%) missed (%) TP, true positive; FN, false negative; FP, false positive; TN, true negative; PPV, positive predictive value. In an attempt to predict PCa, various PSA indices have recently been proposed. Demura et al. (10) claimed that, by using the γ-sp antibody which recognizes free PSA exclusively, the γ-sp/total PSA ratio is useful in discriminating PCa from BPH. However, since their study population contained 34 (26.7%) stage D PCa patients and their PSA cutoff value was set at 3.0 ng/ml, the superiority of γ-sp/psa ratio in detecting localized PCa might be limited. Kurita et al. (24) also reported that γ-sp/total PSA was most useful for detection of PCa with the prostate volume of <40 ml. Although the free/total PSA ratio has been reported as the most useful predictor of PCa, the clinical usefulness of free/total PSA for PCa in the Japanese male population has yet to be adequately demonstrated (25). Furthermore, the discrepancies of the levels of serum free PSA depending on the assay systems have been reported (26). Thus the efficacy of the free/total PSA for the early detection of the PCa must be interpreted carefully. On the other hand, Kanehara et al. (27) and Ohori et al. (28) indicated that PSA density was significantly more accurate than serum PSA levels for the early detection of PCa. Our study revealed that PSA density and total PSA were the most powerful predictors of PCa in the overall range. In the total PSA range between 4.1 and 10.0 ng/ ml, which was described as a gray zone, PSA density was significantly more accurate than total PSA. Taken together, PSA density was found to be the most useful predictor of PCa. PSA density would therefore be the most important criterion for determining whether or not to perform prostate biopsy. Based on the data from Western patients (6,7), a PSA density of 0.15 has been widely used as a cutoff value. Only a few studies have evaluated the optimum PSA density level in predicting PCa for Japanese population. Gohji et al. (29) suggested that PSA density was superior to PSATZ in detecting PCa in Japanese PCa patients with a PSA level of ng/ml and proposed an optimum cutoff value of PSA density of Arai et al. (30) also claimed that PSA density improved the specificity of cancer detection in a Japanese population with a normal digital examination and an intermediate PSA level of ng/ml. They proposed a PSA density of 0.19 in Japanese males as an optimum cutoff value. We found that the optimum PSA density was 0.18 because it gave the highest sum of sensitivity and specificity. Utilizing this, the number of unnecessary biopsies could be reduced to 57 from 63% when compared with a PSA density of The optimum PSA density values for Japanese proposed by us and others (29,30) seem considerably higher than those for Western people. This might come from the differences in physiological and genetic factors of the prostate. The mean size of the prostate gland is smaller and the mean serum PSA value is lower in Japanese males compared with those in white males (31). As PSA is secreted exclusively from the prostate epithelium and periurethral glands (32), the racial difference in the prostate volume may account for the racial difference in serum PSA levels. Meanwhile, Ross et al. (33) reported a significant difference in 5α-reductase activity between Japanese and Caucasians. Kantoff et al. (34) also claimed that a polymorphism of the 5α-reductase gene was associated with an increased risk of PCa. These findings suggest that the racial difference should be considered to standardize the PSA-related variables as predictors of PCa. In conclusion, our results indicated that PSA density is the most useful variable among total PSA, PSA density, γ-sp and γ-sp/total PSA and that a PSA density cutoff value of 0.18 is optimum for differentiating PCa from BPH in the Japanese population with an intermediate serum PSA level. References 1. Silverberg E, Lubera JA. Cancer statistics CA Cancer J Clin 1989;39: Tominaga S, Aoki K, Hani A, Kurihara N. Cancer Statistics Incidence/ Mortality/Prognosis. Tokyo: Shinohara 1993; (in Japanese).
6 342 The clinical utility of measuring total PSA 3. Nixon RG, Brawer MK. Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. Br J Urol 1997;79: Brawer MK. The diagnosis of prostatic carcinoma. Cancer 1993;71: Oesterling JE. Prostate specific antigen; a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145: Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. JUrol1992;147: Benson MC, Olsson CA. Prostate specific antigen and prostate specific antigen density: roles in patient evaluation and management. Cancer 1994;74: Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, et al. Serum prostate specific antigen complexed to alpha1 antichimotrypsin as an indicator of prostate cancer. JUrol1993;150: Luderer AA, Chen YT, Soriaino TF, Kramp WJ, Carlson G, Cuny C, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate specific antigen in the diagnostic gray zone of total prostate specific antigen. Urology 1995;46: Demura T, Watarai Y, Togashi M, Hirano T, Ohashi N, Koyanagi T. A new means of distinguishing benign prostatic hyperplasia and prostate cancer. JUrol1993;150: Carter HB, Pearson JD. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am 1997;24: Kalish J, Cooner WH, Graham SD Jr. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 1994;43: Zlotta AR, Djavan B, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. JUrol1997;157: Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAmMed Assoc 1993;270: Kakizoe T.Cancer Statistics in Japan, Tokyo: Foundation for Promotion of Cancer Research 1997;44 9 (in Japanese). 16. International Union Against Cancer. TNM Atlas, 3rd ed, 2nd rev. New York: Springer 1992: Schaller J, Akiyama K, Tsuda R, Hara M, Marti T, Rickle E. Isolation, characterization and amino-acid sequence of γ-seminoprotein from human seminal plasma. Eur J Biochem 1987;170: Bazinet M, Meshref AW, Trudel C, Aronson S, Peloquin F, et al. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994;43: Metz CE. Some practical issues of experimental design and data analysis in radiological ROC studies. Invest Radiol 1989;24: Hanley HA, McNeil BJ. The meaning and use of area under a receiver operating characteristic (ROC) curve. Radiology 1982;143: Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahman FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver-operating characteristic curves. Urology 1994;152: Kirby RS, Christmas RJ, Brawer MK. Prostate Cancer. London: Mosby 1996; Rietbergen JB, Kruger AE, Kranse R, Schroeder FH. Complications of transrectal ultrasound systemic sextant biopsies of the prostate: evaluation of complication rates and risk factor within a population-based screening program. Urology 1997;49: Kurita Y, Terada H, Masuda H, Suzuki K, Fujita K. Prostate specific antigen (PSA) value adjusted for transition zone volume and free PSA (γ-seminoprotein)/psa ratio in the diagnosis of prostate cancer in patients with intermediate PSA levels. Br J Urol 1998;82: Egawa S, Soh S, Ohori M, Uchida T, Gohji K, Fujii A, et al. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan. Cancer 1997;79: Cattini R, Robinson D, Gill O, Jolley N, Bacarese-Hamilton T. Measurement of prostate specific antigen in serum using four different immunoassays. Eur J Clin Chem Clin Biochem 1994;32: Kanehara H, Ueda H, Katsuoka H. The efficacy of PSA density for the early detection of prostate cancer. Nihon Rinsho 1998;56: (in Japanese). 28. Ohori M, Dunn JK, Scardio PT. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 1995;46: Gohji K, Nomi M, Egawa S, Morisue K, Takenaka A, Okamoto M, et al. Detection of prostate carcinoma using prostate specific antigen, its density and the density of transition zone in Japanese men with intermediate serum prostate specific antigen concentration. Cancer 1997;79: Arai Y, Maeda H, Ishitoya S, Okubo K, Okada T, Aoki Y. Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate antigen levels. JUrol1997;153: Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Masumori N, et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 1995;75: Carter HB, Partin AW. Diagnosis and staging of prostate cancer.in: Walsh PC, Retik AB, Vauhgan ED, Wein AJ, Editors. Campbell s Urology, 7th ed. Tokyo: W.B. Saunders 1998: RossRK,BernsteinL,LoboRA,ShimizuH,StanczykFZ,PikeMC,etal. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339: Kantoff PW, Febbo PG, Giovannucci E, Krithivas K, Dahl DM, Chang G, Hennekens CH, Brown M, Stampfer MJ. A polymorphism of the 5-alphareductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 1997;6:
Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?
ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate
More informationSafety and Efficacy of Combined Transrectal Ultrasound-Guided Prostate Needle Biopsy and Transurethral Resection of the Prostate
www.kjurology.org DOI:10.4111/kju.2010.51.2.101 Urological Oncology Safety and Efficacy of Combined Transrectal Ultrasound-Guided Prostate Needle Biopsy and Transurethral Resection of the Prostate Jeong
More informationTHE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE BIOPSIES IN IMPROVING THE DIAGNOSTIC ABILITY IN PROSTATE CANCER
Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 27 (3): 222-226, May - June, 2001 THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationThe In uence of Prostate Volume on Prostate Cancer Detection
European Urology Supplements European Urology Supplements 1 (2002) 35±39 The In uence of Prostate Volume on Prostate Cancer Detection Michael K. Brawer * Northwest Prostate Institute, Seattle, USA Abstract
More informationUse of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate From Benign Prostatic Disease A Prospective Multicenter Clinical Trial William J. Catalona, MD; Alan W. Partin,
More informationScreening for Prostate Cancer Using Prostate-specific Antigen Alone asafirst-linecheckupparameter:resultsofthehealthcheckup System
Jpn J Clin Oncol 2000;30(2)95 100 Screening for Prostate Cancer Using Prostate-specific Antigen Alone asafirst-linecheckupparameter:resultsofthehealthcheckup System Katsunori Uchida 1, Hitoshi Takeshima
More informationUse of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer {
Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer { (2003) 6, 39 44 ß 2003 Nature Publishing Group All rights reserved 1365 7852/03 $25.00 www.nature.com/pcan
More informationINTEROBSERVER VARIATION OF PROSTATIC VOLUME ESTIMATION WITH DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS WITH DIFFERENT EXPERIENCES
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS Vol. 30 (6): 466-471, November - December, 2004 INTEROBSERVER
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationor more transrectal ultrasonography (TRUS)-guided ng/ml and 39% if it was 20.0 ng/ml. of >10 ng/ml have prostate cancer [3], many other
BJU International (1999), 83, 34 38 Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? G.C. DURKAN
More informationIntroduction. Objective To investigate the clinical significance of the 1.13 ng/ml, P<0.001) and a lower free-to-total PSA
British Journal of Urology (1998), 81, 532 538 Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA
More informationClinical Significance of Prostate Specific Antigen for Early Stage Prostate Cancer Detection
linical Significance of Prostate Specific Antigen for Early Stage Prostate ancer Detection Kyoichi Imai, Yoshio Ichinose, Yutaka Kubota, Hidetoshi Yamanaka, Jin Sato 2, Masahito Saitoh, Hiroki Watanabe
More informationORIGINAL ARTICLE Urology INTRODUCTION
ORIGINAL ARTICLE Urology DOI: 10.3346/jkms.2011.26.1.85 J Korean Med Sci 2011; 26: 85-91 Initial Biopsy Outcome Prediction in Korean Patients- Comparison of a Novel Web-based Korean Prostate Cancer Risk
More informationRole of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53..46 Urological Oncology Role of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
More informationThe Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend
www.kjurology.org http://dx.doi.org/1.4111/kju.212.53.1.686 Urological Oncology The Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend Hyung-Sang
More informationDetermination of Reference Values for Total PSA, Frr and PSAD According to Prostatic Volume in Japanese Prostate Cancer Patients
Jpn J Clin OncoI1999;29(l2)617-622 Determination of Reference Values for Total PSA, Frr and PSAD According to Prostatic Volume in Japanese Prostate Cancer Patients with Slightly Elevated Serum PSA Levels
More informationIs Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen?
www.kjurology.org http://dx.doi.org/1.4111/kju.1.3..8 Urological Oncology Is Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen? Jee
More informationEnzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum
Enzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum FOR RESEARCH USE ONLY Store at 2 to 8 C. PROPRIETARY AND COMMON NAMES f-psa Enzyme Immunoassay
More informationLikelihood of Prostate Cancer Based on Prostate-Specific Antigen Density by MRI: Retrospective Analysis
Journal of Computer Assisted Tomography 26(3):432 437 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Likelihood of Prostate Cancer Based on Prostate-Specific Antigen Density by MRI: Retrospective
More informationCumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio
European Urology European Urology 45 (2004) 160 165 Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio Gunnar Aus a,*, Charlotte Becker b, Stefan
More informationDetermination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer
Original Article DOI: 10.21276/APALM.1254 Determination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer Vineeth* G Nair and M. H. Shariff Department of Pathology, Yenepoya
More informationDeveloping a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection
DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong
More informationEfficacy of Pelvic Diffusion Weighted MRI Prior to Prostate Biopsy in Patients with tpsa Level of 2,5-20 ng/ml for Determination of Malign Lesions
ISPUB.COM The Internet Journal of Urology Volume 14 Number 1 Efficacy of Pelvic Diffusion Weighted MRI Prior to Prostate Biopsy in Patients with tpsa Level of 2,5-20 ng/ml for Determination of Malign Lesions
More informationAge Specific Reference Levels of Serum. Volume and Prostate Specific Antigen. Density in Healthy Iranian Men
ISSN 1735-1383 Iran. J. Immunol. March 2009, 6 (1), 40-48 Abdol Aziz Khezri, Mehdi Shirazi, Seyyed Mohammad Taghi Ayatollahi, Mehrzad Lotfi, Mehrdad Askarian, Ali Ariafar, Mohammad Amin Afrasiabi Age Specific
More informationThe Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
Research Article TheScientificWorldJOURNAL (2009) 9, 343 348 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.47 The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial
More informationAre extended biopsies really necessary to improve prostate cancer detection?
(2003) 6, 250 255 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Are extended biopsies really necessary to improve prostate cancer detection? R Damiano*,1, R
More informationAge-Specific Reference Ranges for PSA in the Detection of Prostate Cancer
Age-Specific Reference Ranges for PSA in the Detection of Prostate Cancer Review Article [1] April 01, 1997 By Edward P. Deantoni, PhD [2] PSA is the best tumor marker yet discovered. Age-specific reference
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationComplexed Prostate-specific Antigen for the Detection of Prostate Cancer
Complexed Prostate-specific Antigen for the Detection of Prostate Cancer XAVIER FILELLA 1, DAVID TRUAN 2, JOAN ALCOVER 2, RAFAEL GUTIERREZ 2, RAFAEL MOLINA 1, FRANCISCA COCA 1 and ANTONIO M. BALLESTA 1
More informationEvaluation of Prostate Specific Antigen as a Tumor Marker in Cancer Prostate
Evaluation of Prostate Specific Antigen as a Tumor Marker in Cancer Prostate Pages with reference to book, From 360 To 363 Farkhanda Ghafoor,Shahzad Khan,Bilquis Suleman,Aman Ullah Khan ( Departments of
More informationUtility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma
Disease Markers 19 (2003,2004) 287 292 287 IOS Press Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma V. Thakur a,, P.P. Singh b, M. Talwar c and U. Mukherjee
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationBone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer?
Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer? Megumi Hirobe 1, Atsushi Takahashi 1, Shin-ichi Hisasue 1, Hiroshi Kitamura 1, Yasuharu Kunishima 1, Naoya Masumori 1, Akihiko
More informationSERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE. A. AMAYO and W.
22 EAST AFRICAN MEDICAL JOURNAL January 2004 The East African Medical Journal Vol. 81 No. 1 January 2004 SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE.
More informationReview of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases
Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,
More informationISSN X (Print) Pradesh. *Corresponding author Dr. Ashish
Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2015; 3(8B):2886-2890 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationAge-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients
(2003) 6, 256 260 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients 1, *
More informationProstate specific antigen and acinar density: a new dimension, the Prostatocrit
ORIGINAL ARTICLE Vol. 43 (2): 230-238, March - April, 2017 doi: 10.1590/S1677-5538.IBJU.2016.0145 Prostate specific antigen and acinar density: a new dimension, the Prostatocrit Simon Robinson 1, Marc
More informationKEY WORDS : Total Prostate Specific Antigen, Prostatic Acid Phosphatase, Benign Prostatic Hyperplasia, Prostate Cancer, and Sudanese.
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 3 Issue 1 January 2014 PP.36-40 Serum Total Prostatic Specific Antigen and Prostatic Acid
More informationSerum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study
european urology 51 (2007) 1645 1653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia Serum Prostate-Specific Antigen as a Predictor of Prostate
More informationBJUI. Study Type Prognosis (individual cohort study) Level of Evidence 2b OBJECTIVES CONCLUSIONS
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTING THE OUTCOME OF PROSTATE BIOPSY HERNANDEZ et al. BJUI BJU INTERNATIONAL Predicting the outcome of prostate biopsy: comparison
More informationOriginal Article - Urological Oncology. Ho Gyun Park 1, Oh Seok Ko 1, Young Gon Kim 1, Jong Kwan Park 1-4
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.4.249 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.4.249&domain=pdf&date_stamp=2014-04-17
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationHistopathological Study of Transrectal Ultrasound Guided Biopsies of Prostate
ORIGINAL ARTICLE Histopathological Study of Transrectal Ultrasound Guided Biopsies of Prostate in Patients With Raised Serum Prostate Specific Antigen Prabha Rathour 1, Hetal Jani 2, Urvi Parikh 3, Hansa
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationAmbulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer
Ambulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer Luigi Benecchi, Anna Maria Pieri, Carmelo Destro Pastizzaro, and Michele Potenzoni OBJECTIVES METHODS RESULTS CONCLUSIONS
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationInt J Clin Exp Pathol 2017;10(6): /ISSN: /IJCEP Yu Chen, Jin Hu, Liang Yan, Junlong Zhang, Liang Zhao
Int J Clin Exp Pathol 2017;10(6):7177-7182 www.ijcep.com /ISSN:1936-2625/IJCEP0045038 Original Article The value of PSA and its derivative indexes on improving the discrimination between NIH-IV prostatitis
More informationPSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine
PSA screening To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine Conflict of Interest Declaration: Nothing to Disclose
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationDoes normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
Original Article Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy? Sherif Azab 1, Ayman Osama 2, Mona Rafaat 3 1 Urology Department, Faculty
More informationEvaluation of a rapid qualitative prostate speci c antigen assay, the One Step PSA TM test
Cancer Letters 162 (2001) 135±139 www.elsevier.com/locate/canlet Evaluation of a rapid qualitative prostate speci c antigen assay, the One Step PSA TM test Chang Dok An a, Tatsuhiro Yoshiki a, *, Gregory
More informationBPH & Male LUTS INJ 2010;14:
BPH & Male LUTS INJ 2010;14:100-104 Changes in Serum Prostate-Specific Antigen after Treatment with Antibiotics in Patients with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia with Prostatitis
More informationAsian J Androl 2005; 7 (2): DOI: /j x
Asian J Androl 5; 7 (2): 159 163 DOI: 1.1111/j.1745-7262.5.29.x. Original Article. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationShrestha A, Chalise PR, Sharma UK, Gyawali PR, Shrestha GK, Joshi BR. Department of Surgery, TU Teaching Hospital, Maharajgunj, Kathmandu, Nepal
Original Article Intravesical Prostatic Protrusion is better than Prostate Volume in Predicting Symptom Severity in Benign Prostatic Hyperplasia: A Prospective Clinical Study Shrestha A, Chalise PR, Sharma
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationISSN: (Print) (Online) Journal homepage:
Archives of Andrology Journal of Reproductive Systems ISSN: 0148-5016 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/iaan19 CHANGE IN INTERNATIONAL PROSTATE SYMPTOM SCORE AFTER TRANSURETHRAL
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationThe Clinical Potential of Pretreatment Serum Testosterone Level to Improve the Efficiency of Prostate Cancer Screening
european urology 51 (2007) 375 380 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Clinical Potential of Pretreatment Serum Testosterone Level to Improve
More informationComputer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd? 200613?12901295Original ArticleAdditional apical biopsy in prostatic gland
More informationDichotomous Estimation of Prostate Volume: A Diagnostic Study of the Accuracy of the Digital Rectal Examination
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2013 December 31(3): 220-225 http://dx.doi.org/10.5534/wjmh.2013.31.3.220 Original Article Dichotomous Estimation of Prostate Volume: A Diagnostic
More informationORIGINAL ARTICLES P ATIE TS A D METHODS. In patients with a PSA > 50 ng/ml, where no pathology RESULTS
-----.- SERUM PROSTATE-SPECIFIC ANTIGEN AS SURROGATE FOR THE HISTOLOGICAL DIAGNOSIS OF PROSTATE CANCER C F Heyns, A M audt'!, G Ahmed, H B Stopforth, G A Stellmacher, A J Visser Introduction. To determine
More informationSubject Review. Percent Free Prostate-Specific Antigen: Entering a New Era in the Detection of Prostate Cancer
Subject Review Percent Free Prostate-Specific Antigen: Entering a New Era in the Detection of Prostate Cancer ApOORVA R. VASHI, M.D., AND JOSEPH E. OESTERLING, M.D. The introduction of prostate-specific
More informationTransrectal ultrasound-guided biopsy for the diagnosis of prostate cancer
Transrectal ultrasound-guided for the diagnosis of prostate cancer Adrian Haşegan Clinica de Urologie, Spitalul Clinic Judeţean de Urgenţă Sibiu Facultatea de Medicină Sibiu Abstract Transrectal ultrasound-guided
More informationAVOID A POTENTIALLY UNNECESSARY REPEAT PROSTATE BIOPSY. The Progensa PCA3 test
AVOID A POTENTIALLY UNNECESSARY REPEAT PROSTATE BIOPSY The Progensa PCA3 test is the first FDA-approved prostate cancer-specific test of its kind that helps you and your doctor decide if a repeat biopsy
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationORIGINAL ARTICLE INTRODUCTION
ORIGINAL ARTICLE Vol. 44 (x): 2018 April 4.[Ahead of print] doi: 10.1590/S1677-5538.IBJU.2017.0506 Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationPredicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort
Predicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort MACIEJ SALAGIERSKI 1, PETER MULDERS 2 and JACK A. SCHALKEN 2 1 Urology Department, Medical University of Łódź, Poland;
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationONCOLOGY LETTERS 8: , 2014
1834 Systematic 12 and 13 core transrectal ultrasound or magnetic resonance imaging guided biopsies significantly improve prostate cancer detection rate: A single center 13 year experience GONG CHENG *,
More informationDetection of prostate cancer by MR-ultrasound fusion guided biopsy
Detection of prostate cancer by MR-ultrasound fusion guided biopsy Poster No.: C-0761 Congress: ECR 2014 Type: Scientific Exhibit Authors: T. Durmus, C. Stephan, T. Slowinski, A. Thomas, A. Maxeiner, B.
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationAge-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men
Original Article KEHINDE et al. Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men ELIJAH O. KEHINDE, OLUSEGUN A. MOJIMINIYI*, MEHRAJ SHEIKH, KALEEL
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationMAKE REPEAT PROSTATE BIOPSY DECISIONS WITH CONFIDENCE. The Progensa PCA3 test
MAKE REPEAT PROSTATE BIOPSY DECISIONS WITH CONFIDENCE The Progensa PCA3 test is the first FDA-approved prostate cancer-specific test of its kind that gives you the information you need to determine if
More informationProstate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph
Prostate cancer screening: a wobble Balance Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Epidemiology Most common non skin malignancy in men in developed countries Third leading
More informationJMSCR Vol 05 Issue 03 Page March 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i3.135 Diagnosis of Carcinoma Prostate Based
More informationThe Prevalence and Characteristic Differences in Prostatic Calcification between Health Promotion Center and Urology Department Outpatients
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.5.330 Voiding Dysfunction The Prevalence and Characteristic Differences in Prostatic Calcification between Health Promotion Center and Urology Department
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationOwing to the widespread use of prostate specific antigen (PSA)
ORIGINAL RESEARCH Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation Moamen M. Amin, MD; Suganthiny Jeyaganth, MSc; Nader Fahmy,
More informationRELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
American Urological Association symptom index for BPH RELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTION IN PATIENTS WITH
More informationMEDICAL POLICY SUBJECT: TRANSRECTAL ULTRASOUND (TRUS)
MEDICAL POLICY SUBJECT: TRANSRECTAL ULTRASOUND 06/16/05, 05/18/06, 03/15/07, 02/21/08 PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under
More informationProstatic Diseases and Male Voiding Dysfunction
Prostatic Diseases and Male Voiding Dysfunction Prostatic-specific Antigen Velocity After Holmium Laser Enucleation of the Prostate: Possible Predictor for the Assessment of Treatment Effect Durability
More informationAGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN IN BLACK MEN. The New England Journal of Medicine
AGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN IN BLACK MEN TED O. MORGAN, M.D., STEVEN J. JACOBSEN, M.D., PH.D., WILLIAM F. MCCARTHY, PH.D., DEBRA J. JACOBSON, M.S., DAVID G. MCLEOD,
More information. ORIGINAL ARTICLES SERUM PROSTATE-SPECIFIC ANTIGEN AS SURROGATE FOR THE HISTOLOGICAL DIAGNOSIS OF PROSTATE CANCER
. SERUM PROSTATE-SPECIFIC ANTIGEN AS SURROGATE FOR THE HISTOLOGICAL DIAGNOSIS OF PROSTATE CANCER C F Heyns, AM Naude, G Ahmed, H B Stopforth, G A Stellmacher, A J Visser Introduction. To determine whether
More informationNEURO-FUZZY SYSTEM FOR PROSTATE CANCER DIAGNOSIS LUIGI BENECCHI
ADULT UROLOGY NEURO-FUZZY SYSTEM FOR PROSTATE CANCER DIAGNOSIS LUIGI BENECCHI ABSTRACT Objectives. To develop a neuro-fuzzy system to predict the presence of prostate cancer. Neuro-fuzzy systems harness
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationBPH AND BEYOND. BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD
BPH AND BEYOND B: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD Baylor Prostate Center, The Scott Department of Urology, Baylor College
More informationOriginal Article The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men 50 years
Am J Clin Exp Urol 2014;2(4):332-336 www.ajceu.us /ISSN:2330-1910/AJCEU0002941 Original Article The implications of prostate-specific antigen density to predict clinically significant prostate cancer in
More informationOriginal Article. Introduction. Xin LIU 1, *Jie TANG 2, Xiang FEI 2, Qiu-Yang LI 2
Original Article Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less Xin LIU 1, *Jie TANG 2, Xiang
More informationSubject Review. Prostate-Specific Antigen: Critical Issues for the Practicing Physician
Subject Review Prostate-Specific Antigen: Critical Issues for the Practicing Physician HERBERT C. RUCKLE, M.D.,* GEORGE G. KLEE, M.D., PH.D., AND JOSEPH E. OESTERLING, M.D. Background: Serum prostate-specific
More informationNomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy
Original Article Prostate Int 2013;1(2):69-75 P R O S T A T E INTERNATIONAL Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy
More informationProstate Cancer 3/15/2017. CEUS of the Prostate. The Prostate Cancer Screening Dilemma Data. Incidence: 161,360 Deaths: 26,730
Prostate Cancer CEUS of the Prostate 2017 Data Incidence: 161,360 Deaths: 26,730 Third leading cause of cancer death in men (after lung & Professor of Radiology & Urology colon Ca) Co-Director, Jefferson
More information